Immunomedics (IMMU)
Add to Watchlists Create an Alert
3.36
+0.08 +2.44%
NASDAQ
May 24, 8:00PM
BATS Real time
Currency in USD
Immunomedics Revenue Quarterly YoY Growth:
-97.26% for Dec. 31, 2012Immunomedics Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | -97.26% |
| Sept. 30, 2012 | -8.15% |
| June 30, 2012 | -91.34% |
| March 31, 2012 | -11.52% |
| Dec. 31, 2011 | 2855% |
| Sept. 30, 2011 | -23.37% |
| June 30, 2011 | 81.79% |
| March 31, 2011 | -89.74% |
| Dec. 31, 2010 | -80.31% |
| Sept. 30, 2010 | -96.17% |
| June 30, 2010 | -26.30% |
| March 31, 2010 | 28.70% |
| Dec. 31, 2009 | -40.14% |
| Sept. 30, 2009 | 696.1% |
| June 30, 2009 | 761.2% |
| March 31, 2009 | 818.4% |
| Dec. 31, 2008 | 750.3% |
| Sept. 30, 2008 | 527.3% |
| June 30, 2008 | 14.94% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
| Sept. 30, 2000 | Go Pro |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
IMMU Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Seattle Genetics | 30.73% |
| AVEO Pharmaceuticals | -62.44% |
| Threshold Pharmaceuticals | 1060% |
IMMU Revenue Quarterly YoY Growth Rankings
| Overall |
38th percentile 4889 of 8011 |
| Sector |
26th percentile 507 of 687 in Healthcare |
| Industry |
42nd percentile 143 of 248 in Biotechnology |
IMMU Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -97.26% | Dec 2012 |
| Maximum | 2855% | Dec 2011 |
| Average | 314.2% |
